Aerys Biosciences at JPM 2026 San Francisco.
Rabindra Shivnaraine, Director of Clinical Pharmacology at Aerys Biosciences, attended the 2026 J.P. Morgan Healthcare Conference in San Francisco.Aerys Biosciences is advancing innovative, first-in-class, disease-modifying therapies for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Participants with Idiopathic Pulmonary Fibrosis (SAFE-IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including up to 4 weeks for screening, followed by 12 weeks of oral […]
Aerys Biosciences at OCT West Coast 2026
Rabindra Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, spoke at Outsourcing in Clinical Trials West Coast 2026 during the panel on Emerging Biotech vs. Big Pharma. Dr. Shivnaraine emphasized the importance of executing First-in-Human trials efficiently, leveraging lean outsourcing models, and building trusted CRO partnerships to accelerate development. Emerging biopharma companies like Aerys […]
Aerys Biosciences at the Pulmonary Fibrosis Foundation Summit – 25th Anniversary
Robin Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, attended the 25th Anniversary Summit of the Pulmonary Fibrosis Foundation in November 2025, held in Chicago, Illinois.The meeting brought together patients, clinicians, researchers, and industry leaders to mark 25 years of progress in pulmonary fibrosis research and care. During the Summit, Dr. Shivnaraine engaged with […]
Aerys Biosciences at J.P. Morgan Healthcare Conference
Robin Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, will attend the J.P. Morgan Healthcare Conference, January 12–15, 2026, in San Francisco, California.Dr. Shivnaraine is seeking meetings with clinical development partners and funding organizations interested in collaborating on programs for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Aerys Biosciences Panelist at Outsourcing Clinical Trials West Coast
Robin Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, will serve as a panelist at Outsourcing Clinical Trials West Coast, February 11–12, 2026, in San Francisco, California.Dr. Shivnaraine will share practical insights on coordinating and executing clinical trials as a small, emerging biotech, drawing on hands-on experience advancing early-stage pulmonary programs.
Aerys Biosciences at Stanford Drug Discovery Symposium (SDDS) 2026
Robin Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, will attend the Stanford Drug Discovery Symposium (SDDS) 2026, held April 27–28, 2026, at Stanford University, California.SDDS brings together academic, industry, and investment leaders to highlight advances across the drug discovery and translational development pipeline. Dr. Shivnaraine will engage with collaborators and peers to discuss […]